companion - MSD Animal Health (Australia)

Parainfluenza (Inactivated)
Bordetella (Inactivated)
Parainfluenza (MLV)
Adenovirus type 2 (MLV)
Parvovirus (MLV)
Distemper (MLV)
Recommended vaccination protocols
Vaccine
Vaccine
Companion C3
Companion C4
®
®
Presentation
Companion C3
•
•
•
Companion C4
•
•
•
®
®
10 doses
•
®
10 doses
•
Companion® KC
Companion® C5
Pack
Companion KC
•
10 doses
10 doses Companion® C3 + 10 doses
Companion® KC
Primary vaccination
Puppies from 8 to 12
weeks of age:
Inject 2 doses of vaccine
at an interval of 1 month
Dogs over 12 weeks
of age:
For C3 - inject a single
dose of vaccine
For C4 - inject 2 doses 1
month apart
COMPANION
Inject 2 doses of vaccine
at an interval of 1 month
to dogs 6 weeks of age
or over
An annual booster is recommended
for all vaccines
Recommended vaccination protocols
Feline Herpes virus
(MLV)
Feline Calicivirus
(MLV)
Modified-live virus (MLV) vaccine
• Canine Distemper virus
• Canine Adenovirus type 2
• Canine Parvovirus
• +/- Canine Parainfluenza virus
Feline leukaemia
(Recombinant)
COMPANION
C3 AND C4
®
Feline panleucopaenia
(MLV)
Vaccine
Vaccine
Presentation
Companion® F3
Early socialisation in puppies
• 12 week finish
• Flexibility for 3 dose, 16 week finish protocol if desired
•
•
Companion FeLV
®
Annual boosters
•
10 doses
•
10 doses
Primary vaccination
®
Companion F3
Kittens from 8 to 12
weeks of age:
Inject 3 doses of vaccine
at an interval of 1 month
Cats over 12 weeks
of age:
Inject 2 doses of vaccine
at an interval of 1 month
Companion
FeLV
®
Inject 2 doses of vaccine
at a 2 to 3 week interval
to cats 9 weeks of age
or over
An annual booster is recommended
for all vaccines
REFERENCES
Protective efficacy of each antigen
demonstrated in challenge trials
1
Provides protective immunity against all
field strains of canine parvovirus
2
Safety trials demonstrated no reversion to
virulence for any antigen
3
1. Data on file, study numbers: DA08E002,
DA08E003, 912.04/0007, DA08E004,
912.04/008, DA08E005, 912.04/10.
2. Day MJ, Horzinek MC & Schultz RD (2007)
Guidelines for the vaccination of dogs and cats.
WSAVA Vaccination Guidelines Group. p.33.
3. Data on file, study numbers: DM01I001,
CHPPiI003, CHPPiI002, CHPPiI005.
4. Data on file: Antibody, challenge and safety
studies (Registration dossier, Part III, pages 22-83)
5. O’Brien C (2007) Feline Vaccinations – a review.
The Veterinarian, March: 25-27.
6. Richards JR et al. The 2006 American Association
of Feline Practitioners Feline Vaccine Advisory
Panel Report.
7. Horzinek MC & Thiry E (2009) Vaccines and
vaccination: the principles and the polemics.
Journal of Feline Medicine and Surgery 11,
530-537.
8. Safety trials for APVMA Registration 40759.
9. Jarrett O & Ganiere J-P (1996) Comparative
studies of the efficacy of a recombinant feline
leukaemia virus vaccine. Veterinary Record
138, 7-11.
10.Hofmann-Lehmann R et al (2007) Vaccination
against feline leukaemia virus: Outcome and
response categories and long-term follow-up.
Vaccine 25, 5531-5539.
11.Clark N et al (1991) Efficacy and safety field
trials of a recombinant DNA vaccine against
feline leukaemia virus infection. Journal of the
American Veterinary Medical Association 199
(10): 1433-43.
C3 can be reconstituted with Companion
KC to permit administration of a single
‘C5’ vaccination
®
CANINE & FELINE VACCINES
Intervet/Schering-Plough Animal Health
91-105 Harpin Street, Bendigo East VIC 3550
Free Call: 1800 033 461 • Free Fax: 1800 817 414
[email protected] • www.intervet.com.au
COMPANION KC
COMPANION F3
COMPANION FeLV
Inactivated vaccine
• Bordetella bronchiseptica (Bb)
• Canine Parainfluenza (CPi) virus
Modified-live virus (MLV) vaccine
• Feline Herpes virus
• Feline Calicivirus
• Feline Panleucopaenia
Recombinant vaccine
• Feline Leukaemia virus
®
®
Significant protection
demonstrated in challenge trials
9-11
Use from 6 weeks of age
MLV vs Inactivated feline vaccines
Annual boosters
Provides convenience of administration
for fractious dogs
Challenge trial demonstrated significant
protection against Bb and CPi
4
Can be used as a diluent to reconstitute
Companion C3 to permit administration
of a single ‘C5’ vaccination.
®
®
MLV
• No adjuvant required to stimulate immunity
• Have a rapid onset of immunity
• More likely to induce a broad range of immune
responses (humoral and cell-mediated immunity)
• Live agent vaccines are better able to overcome MDA in young kittens than are inactivated agent vaccines
5
5
Excellent safety demonstrated
under field conditions
11
Annual boosters
Can be used as a diluent to
reconstitute Companion F3
®
6
Inactivated
• Adjuvant required to stimulate immunity
• With ‘killed’ preparations, the chemical or physical
treatment used to inactivate the infectivity may damage
or modify the immunogenicity, which usually results in
an immune response of shorter duration, a narrower
antigenic spectrum, and weaker cell-mediated and
mucosal immune responses
• Immunity induced by killed agent vaccines is therefore
less likely to provide effective levels of secretory IgA or
complete cell-mediated immune protection at mucosal
surfaces in the respiratory and gastrointestinal tracts
7
6
Safety trials demonstrated no disease when
vaccine virus was administered intranasally
8
Technical Services
Experienced veterinarians are available to
provide technical support for Intervet/ScheringPlough’s extensive product range.
Services and advice include:
• Vaccination protocols
• Questions re label claims
• Monitoring of post-registration product performance
• Product complaint investigations
Annual boosters
Can be reconstituted with Companion FeLV
®
✆1800 033 461
Call to speak to one of our Technical Services Veterinarians